Cannect buys digital pharmacy Pill, targets US$51.2M revenue by 2028
What's the deal? Brazil's Grupo CannectDealroom has a profile for this one. Try Dealroom →, a health platform specialised in medical cannabis, acquired digital pharmacy PillDealroom has a profile for this one. Try Dealroom → on Monday, August 3. The deal price was not disclosed. CannectDealroom has a profile for this one. Try Dealroom → adds Pill's 150,000 subscription customers to its existing base of 100,000.
What's the endgame? Founded in 2021 by Allan Paiotti and Fernando Domingues, Cannect wants to move beyond cannabis into chronic disease treatment broadly. The group now projects revenue above US$51.2M by the end of 2028.
Why now? Cannect says Pill solves the main challenge in chronic care: patients dropping treatment. The combined platform lets patients schedule automatic medication delivery, reducing missed refills.
With the acquisition, Cannect expands access to more than 17,000 medications, adding cardiology, pneumology, nephrology, gastroenterology, and oncology to its existing neurology, psychiatry, pediatrics, geriatrics, and endocrinology specialists.
"Caring for a chronic disease requires active, continuous follow-up," Paiotti said. "By integrating Pill into Grupo Cannect, we expand available treatments for any chronic condition." Technical integration has begun and will roll out over three months.
By the numbers: Cannect has raised US$10.2M since 2021, including a seed round above US$2.56M and a 2023 round led by Supera CapitalDealroom has a profile for this one. Try Dealroom → — which groups Globo VenturesDealroom has a profile for this one. Try Dealroom →, Luciano Huck, Gilberto Sayão, and Duda Melzer — and BluStoneDealroom has a profile for this one. Try Dealroom →. Mexican fund YaaX CapitalDealroom has a profile for this one. Try Dealroom → also participated.
The signal: Brazil's medical cannabis market moved US$248.4M in 2025, serving about 873,000 patients, per Kaya MindDealroom has a profile for this one. Try Dealroom →. Globally, Fortune Business InsightsDealroom has a profile for this one. Try Dealroom → valued the industry at $22 billion last year, projecting $134 billion by 2034. Cannect's diversification into chronic care suggests operators are hedging beyond cannabis to build broader, recurring healthcare platforms.
Read more: Exame
Image credit: Muffet
